Shilpa Medicare's Stellar Q3 FY26: A Deep Dive into Record Performance and Strategic Growth

Shilpa Medicare Limited, a prominent Indian pharmaceutical company, has delivered an exceptional performance in the third quarter and nine months of the financial year 2026, marking a period of robust growth and strategic advancements. The company reported its highest ever quarterly revenue and EBITDA, underscoring the effectiveness of its R&D-driven business model focused on high-value, limited-competition products. This quarter's results reflect a strong execution across its diversified verticals, setting a confident tone for the future.

For the nine-month period ending December 31, 2025, Shilpa Medicare achieved a consolidated total revenue of INR 1,110 crores, registering a commendable 14% year-on-year growth. The gross profit stood at INR 792 crores, up 19% from the previous year, with gross margins expanding by approximately 300 basis points to 71%, attributed to a favorable product mix. The company's EBITDA for 9MFY26 came in at INR 323 crores, growing 26% year-on-year, with EBITDA margins improving by about 300 basis points to 29%. Notably, the adjusted PAT for 9MFY26 soared to INR 146 crores, a remarkable 128% increase year-on-year, nearly doubling the full-year PAT of FY25 and demonstrating significant bottom-line acceleration. This strong financial momentum is a testament to Shilpa Medicare's disciplined capital allocation and operational efficiency.

Segmental Performance: Drivers of Growth

The company's performance was significantly bolstered by strong contributions from its key business segments. The Formulations vertical was a standout, growing by an impressive 50% year-on-year. This growth was primarily fueled by robust traction in the EU business, which reported over 100% year-on-year revenue growth, alongside improved performance in domestic formulations and sustained market share gains for its 505(b)(2) assets in the US. The API segment also demonstrated healthy growth, supported by newly expanded capacities and a strong demand environment, particularly in its non-oncology portfolio.

In the Biologics segment, Shilpa Medicare is witnessing strong traction with steady progress in its key pipeline assets. The company's strategic focus on differentiated R&D-driven business models, centered on high-value, limited-competition products, continues to yield positive results. This approach allows Shilpa Medicare to invest in R&D, build differentiated assets, launch them with strong margins, and scale through strategic partnerships.

Strategic Initiatives and Future Outlook

Shilpa Medicare's strategic initiatives are clearly aligned with its growth objectives. The successful launch of NorUDCA (Nor-Ursodeoxycholic Acid Tablets 500 mg) for Non-alcoholic Fatty Liver Disease (NAFLD) in India has been a significant milestone. This first-in-class therapy, launched under the company's own brand Noduca™ and through partnerships with three large pharma companies, has exceeded expectations, with global regulatory efforts underway for Europe and the US.

The company also achieved a major regulatory success with the EU approval for its Rotigotine Transdermal Patch, with a launch planned in FY27. Furthermore, Shilpa Medicare filed its first transdermal patch ANDA to the USFDA for Rotigotine, targeting a USD 112 million market. In the Biologics space, Shilpa's first ADC biosimilar is expected to enter human studies in FY27, and its mAbTree Biologics product received FDA Orphan Drug Designation for rare blood cancers, highlighting its commitment to novel therapies.

Looking ahead, Shilpa Medicare is investing in a large-scale peptide manufacturing capacity, specifically targeting GLP-1 products like Semaglutide, anticipating significant market opportunities as patents expire. The company's management expressed confidence in a significantly better FY27, driven by continued progress across all verticals, improved capital efficiency, and strategic partnerships. The adjusted ROCE, excluding investments in high-growth potential biologics and NBE businesses, has seen a significant improvement from 3.4% in FY23 to 17.1% in 9MFY26, signaling efficient asset utilization.

Conclusion: Sustained Momentum and Strategic Clarity

Shilpa Medicare Limited's Q3 FY26 performance is a clear indicator of its sustained momentum and strategic clarity. The company's ability to achieve record revenues and EBITDA, coupled with significant advancements in its product pipeline and regulatory approvals, positions it strongly for future growth. The focus on differentiated products, integrated CDMO offerings, and high-value biologics, supported by a robust R&D foundation and strategic partnerships, underscores a confident outlook. Shilpa Medicare is not just growing its numbers; it is strategically building a resilient and innovative pharmaceutical enterprise, poised for continued success in the global healthcare landscape.